|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 94 No. 1 (July 1), 1999:
pp. 233-243
The Importance of Antibody-Specificity in Determining Successful
Radioimmunotherapy of B-Cell Lymphoma
Timothy M. Illidge,
Mark S. Cragg,
Harry M. McBride,
Ruth R. French, and
Martin J. Glennie
From the Tenovus Research Laboratory, Southampton University
Hospitals, Southampton, UK.
We report the radioimmunotherapy of mouse B-cell lymphoma,
BCL1, using a panel of anti-B-cell monoclonal antibodies
(MoAb) (anti-CD19, anti-CD22, anti-major histocompatibility complex
(MHC) II, and anti-idiotype (Id) radiolabeled with 131-iodine. When administered early in disease (day 4), the 131I-anti-MHCII
MoAb cured tumors as a result of targeted irradiation alone, the
unlabeled MoAb being nontherapeutic. In contrast,
131I-anti-Id, despite targeting irradiation and having
therapeutic activity as an unconjugated antibody, protected mice for
only 30 days; 131I-anti-CD19 and anti-CD22 were
therapeutically inactive. Binding and biodistribution studies showed
that the anti-Id, unlike anti-MHCII, MoAb was cleared from target cells
in vivo and delivered 4 times less irradiation to splenic tumor.
Treating later in the disease (day 14) increased tumor load and
produced the expected reduction in therapeutic activity with the
anti-MHCII, but surprisingly, allowed 131I-anti-Id to cure
most mice. This unexpected potency of 131I-anti-Id late in
the disease appeared to result from the direct cytotoxicity of the
anti-Id MoAb, which was more active in established disease, in
combination with targeted irradiation. We believe the ability of
targeted irradiation and certain cytotoxic MoAb to work cooperatively
against tumor in this way has important implications for the selection
of reagents in radioimmunotherapy of B-cell lymphoma.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Martensson, R. Nilsson, T. Ohlsson, H.-O. Sjogren, S.-E. Strand, and J. Tennvall
Reduced Myelotoxicity with Sustained Tumor Concentration of Radioimmunoconjugates in Rats after Extracorporeal Depletion
J. Nucl. Med.,
February 1, 2007;
48(2):
269 - 276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Vose
Bexxar(R): Novel Radioimmunotherapy for the Treatment of Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma
Oncologist,
April 1, 2004;
9(2):
160 - 172.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Du, J. Honeychurch, M. S. Cragg, M. Bayne, M. J. Glennie, P. W. M. Johnson, and T. M. Illidge
Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy
Blood,
February 15, 2004;
103(4):
1485 - 1494.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Hindorf, O. Linden, L. Stenberg, J. Tennvall, and S.-E. Strand
Change in Tumor-absorbed Dose due to Decrease in Mass during Fractionated Radioimmunotherapy in Lymphoma Patients
Clin. Cancer Res.,
September 1, 2003;
9(10):
4003S - 4006.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Honeychurch, M. J. Glennie, P. W. M. Johnson, and T. M. Illidge
Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma
Blood,
August 15, 2003;
102(4):
1449 - 1457.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Riccobene, R. C. Miceli, C. Lincoln, Y. Knight, J. Meadows, M. G. Stabin, and C. Sung
Rapid and Specific Targeting of 125I-Labeled B Lymphocyte Stimulator to Lymphoid Tissues and B Cell Tumors in Mice
J. Nucl. Med.,
March 1, 2003;
44(3):
422 - 433.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Buchsbaum and A. F. LoBuglio
Targeting of 125I-Labeled B Lymphocyte Stimulator
J. Nucl. Med.,
March 1, 2003;
44(3):
434 - 436.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Honeychurch, A. L. Tutt, T. Valerius, I. A. F. M. Heijnen, J. G. J. Van de Winkel, and M. J. Glennie
Therapeutic efficacy of Fcgamma RI/CD64-directed bispecific antibodies in B-cell lymphoma
Blood,
November 15, 2000;
96(10):
3544 - 3552.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
